The transaction is expected to close in the second quarter of Nichi-Iko’s fiscal year in March 2017. The acquisition also raises the company’s profile as a key player in the domestic and international generics market, particularly in the U.S.
Officials at Nichi-Iko said they do not anticipate any changes to Sagent’s current operations and management team.
More issues about transactions and valuations:
Ministry Door County Medical Center, Hospital Sisters Health System pursue formal partnership
NYU Langone, Winthrop-University Hospital to begin merger talks
Henderson Hospital hiring for hundreds of open positions
